Business Wire

CA-USERTESTING

13.7.2022 15:02:08 CEST | Business Wire | Press release

Share
UserTesting Enhances Its Machine Learning-Powered Post-Test Analysis and Redesigns Its Platform Experience for Improved Team Collaboration

UserTesting (NYSE: USER), a leader in video-based human insight , today announced advanced Instant Insight features, powered by machine learning, to help companies expedite the analysis of human insights at the test-level and accelerate time to insights. Using data-automation and proprietary models, the UserTestingⓇ Human Insight Platform can detect patterns and anomalies in the customer data, and automatically surface high-value insights within the Customer Experience Narratives. The latest product updates are designed to help companies uncover key customer perspectives more quickly, so team members can understand where to focus their efforts for greater success. In addition to English and German, UserTesting is now available in French, and customers can test in the French language with access to French speaking contributors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005310/en/

New features in this product release:

Discover Patterns and Key Customer Takeaways More Quickly with Test-Level Instant Insights
UserTesting’s test-level Instant Insight feature utilizes data-driven automation and machine learning models to accelerate post-test analysis by automatically detecting patterns, anomalies, and key insights within customer data across multiple tasks and sessions. Customers can quickly identify important takeaways from their tests while alleviating the burden of lengthy post-test analysis.

Intuitively Navigate and Collaborate with UserTesting
UserTesting’s navigation redesign enables customers to access core functionalities more readily, with a new user interface, folder management, easily accessible resources, and a workspace switcher. Updates make the testing and insight management process more intuitive and accessible for broader team use, enabling scalability for growing teams across organizations. Additionally, IT departments can now manage team access more seamlessly with self-service, single sign-on, providing more governance for enterprise-scale deployments.

A Redesigned Card Sorting Experience
UserTesting has enhanced its card sorting capabilities within the UserTesting Human Insight Platform so users can view video feedback alongside card sorting metrics and gather a complete understanding of contributors’ mental models with this streamlined solution. Companies can build navigation or sitemaps based on customer expectations and behaviors, and describe categories to drive better engagement. This helps companies save costs and adapt to rapidly changing customer needs, or changes to their respective businesses, with timely feedback of how digital properties are organized and used.

En français … UserTesting
UserTesting is now available in French for both customer and contributor experiences. Companies looking to get feedback from French-speaking consumers can now do so with the UserTesting Human Insight Platform, as tests can be conducted in French, with French-speaking contributors, giving organizations the ability to target and connect with more people around the world.

Now Supports Native Video/Audio Testing
For companies wanting to test sensitive media content with greater efficiency, UserTesting enables customers to securely upload audio, video, and other media assets directly onto the Human Insight Platform with its new native media asset testing feature. Companies can gather contributor feedback easily on unreleased assets, like video and audio files, before launching them to the public.

“More than ever, it’s imperative that companies know how their customers feel, and why. UserTesting is continuously innovating its platform to help companies gain actionable insights so they can make smarter and faster business decisions,” said Kaj van de Loo, CTO at UserTesting. “UserTesting’s data-driven automation helps customers speed up analysis of video feedback, so they can make decisions quicker than ever. The platform helps companies optimize the use of human insights, so that they can better understand what is driving customer behavior, and adapt to any changes in the market.”

UserTesting will be hosting a webinar highlighting its latest product release on August 3 at 11:00 a.m. PT/2:00 p.m. ET. Register for the webinar here .

About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye